<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Cytomegalovirus infection in pregnancy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Cytomegalovirus infection in pregnancy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Cytomegalovirus infection in pregnancy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Suresh B Boppana, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lisa Hui, MBBS, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Louise Wilkins-Haug, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Martin S Hirsch, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Vanessa A Barss, MD, FACOG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 08, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cytomegalovirus (CMV) is a ubiquitous DNA herpesvirus. As with other herpesviruses, it becomes latent after a primary infection but can reactivate and renew viral shedding. Shedding can occur from multiple sites and for prolonged periods of time. Reinfection with a different viral strain is also possible.
        </p>
        <p>
         CMV is the most common congenital viral infection, with pooled birth prevalence of 0.67 percent in a meta-analysis of worldwide studies [
         <a href="#rid1">
          1-6
         </a>
         ]. Approximately 90 percent of newborns with congenital CMV infection are apparently asymptomatic at birth and 10 percent are symptomatic. Clinical findings in symptomatic neonates are nonspecific and include petechiae, jaundice, hepatosplenomegaly, small size for gestational age, and microcephaly. Both symptomatic and asymptomatic infected newborns are at risk for adverse outcome, but symptomatic newborns are at higher risk [
         <a href="#rid7">
          7-13
         </a>
         ]. Sensorineural hearing loss is the most common sequela of congenital CMV infection, occurring in 33 to 50 percent of symptomatic infants and approximately 25 percent of asymptomatic infants. Clinical features, management, and long-term sequelae of congenital CMV infection in symptomatic and asymptomatic infected newborns are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/14430.html" rel="external">
          "Congenital cytomegalovirus infection: Clinical features and diagnosis", section on 'Symptomatic neonate'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/98188.html" rel="external">
          "Congenital cytomegalovirus infection: Management and outcome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3675891581">
         <span class="h1">
          MATERNAL ISSUES
         </span>
        </p>
        <p class="headingAnchor" id="H1630047517">
         <span class="h2">
          Terminology
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Primary
         </strong>
         <strong>
          maternal CMV infection
         </strong>
         is defined as acquisition of CMV virus during pregnancy in a person with no preexisting CMV-specific immunoglobulin G (IgG) antibodies. The diagnosis is based on
         <strong>
          seroconversion
         </strong>
         (ie, newly detectable CMV-specific antibodies) during pregnancy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nonprimary maternal CMV infection
         </strong>
         is defined as CMV replication in a pregnant individual with
         <strong>
          seroimmunity
         </strong>
         (ie, preexisting CMV-specific IgG antibodies). Like other herpesviruses, CMV establishes latency after the host is initially infected. Maternal antibodies to CMV do not prevent reactivation of latent virus, especially in immunocompromised hosts, or reinfection with a different CMV strain. Reactivation or reinfection during pregnancy can lead to transient viremia and fetal infection [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H314463626">
         <span class="h2">
          Acquisition and vertical transmission
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Maternal acquisition
         </strong>
         – CMV has been cultured from multiple body fluids, including urine, saliva, nasopharyngeal secretions, tears, cervical and vaginal secretions, semen, blood, and breast milk. (See
         <a class="medical medical_review" href="/z/d/html/8289.html" rel="external">
          "Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent adults", section on 'Transmission'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Maternal acquisition from exposure to body fluids can occur via multiple routes, including:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Close nonsexual contact with saliva or urine, although transmission from respiratory droplets or aerosolized droplets is unlikely [
         <a href="#rid15">
          15
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sexual contact
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Transfusion
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Organ transplant
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vertical transmission
         </strong>
         – Maternal viremia, leading to placental infection, and subsequent transplacental transmission to the fetus is the major route of vertical transmission. Placental cytotrophoblasts are permissive to CMV replication.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Newborns may become infected via intrapartum exposure to cervical/vaginal viral shedding or, more commonly, from consumption of infected breast milk. This is unlikely to cause clinical sequelae in healthy full-term neonates, but symptomatic infection can occur in preterm infants. Very low birth weight infants are especially at risk for severe CMV disease. (See
         <a class="medical medical_review" href="/z/d/html/5965.html" rel="external">
          "Overview of cytomegalovirus infections in children", section on 'Early postnatal infection'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5965.html" rel="external">
          "Overview of cytomegalovirus infections in children", section on 'Early postnatal infection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11649401">
         <span class="h2">
          Seroprevalence
         </span>
         <span class="headingEndMark">
          —
         </span>
         CMV infection is common. A systematic survey of the literature estimated 86 percent CMV seroprevalence globally in females of childbearing age [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         Seroprevalence increases with age and varies by demographic factors [
         <a href="#rid2">
          2-4,16,17
         </a>
         ]. The following characteristics have been associated with positive CMV serology in females of childbearing age:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Household and/or occupational exposure to children under age 3 years, especially if they are in daycare [
         <a href="#rid3">
          3,18,19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age older than 25 to 30 years [
         <a href="#rid3">
          3,20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Higher parity [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Country of residence. The highest seroprevalences are in the Eastern Mediterranean, Western Pacific, African, and Southern and Southeast Asian regions (seroprevalence 89 to 92 percent) and the lowest in the European region and the Americas (seroprevalence 70 and 79 percent, respectively) [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Income level of maternal country of birth. In a high-income multicultural society, being born in a non-
         <strong>
          Organisation for Economic Cooperation and Development
         </strong>
         (OECD) country was the only significant factor associated with seroprevalence in a pregnant population, after adjusting for parity and socioeconomic status of current residential postcode [
         <a href="#rid22">
          22
         </a>
         ]. Neighborhood-level poverty as measured by the Area Deprivation Index (ADI) is a race-independent predictor of local CMV seroprevalence among pregnant people in the United States [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H674777058">
         <span class="h2">
          Epidemiology of seroconversion
         </span>
         <span class="headingEndMark">
          —
         </span>
         The likelihood of seroconversion depends on social, behavioral, and environmental factors. Annual rates of seroconversion during pregnancy are generally reported to be 1 to 7 percent worldwide in populations with low-to-intermediate CMV seroprevalence [
         <a href="#rid24">
          24
         </a>
         ]. Seronegative pregnant people living in high-seroprevalence areas are at higher risk; estimated annualized rates of seroconversion of 14.8 to 22.5 percent have been reported in these individuals [
         <a href="#rid25">
          25-27
         </a>
         ]. In a large prospective study from Brazil in which 98 percent of participants were CMV seropositive during the first trimester, 5 out of 36 (13.9 percent) seronegative mothers seroconverted during pregnancy [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         In a systematic review of studies that measured rates of CMV seroconversion, summary annual rates of seroconversion in specific groups were as follows [
         <a href="#rid24">
          24
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnant individuals – 2.3 percent (95% CI 2.1-2.4 percent). However, in a contemporary study that screened over 200,000 pregnant people less than 23 weeks of gestation in the US, only 0.35 percent had serological evidence of primary CMV infection [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Health care workers, including those caring for infants and children – 2.3 percent (95% CI 1.9-2.9 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Daycare providers – 8.5 percent (95% CI 6.1-11.6 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Parents of a young child:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Not shedding CMV – 2.1 percent (95% CI 0.3-6.8 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Shedding CMV – 24 percent (95% CI 18-30 percent). In a previously unexposed parent, this is the scenario with the highest risk of acquisition, presumably through sharing drinks, utensils, and care needs. (See
         <a class="local">
          'Behavioral risk reduction interventions'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Other groups with elevated risk of seroconversion included cohabitating individuals with a CMV-shedding member, female adolescents from disadvantaged groups, individuals attending sexually transmitted disease clinics, and immunocompromised individuals.
        </p>
        <p>
         The risk related to parenthood was illustrated in a study in which 15.6 percent of females seronegative at their first pregnancy seroconverted by the time of a subsequent pregnancy that occurred within two years [
         <a href="#rid29">
          29
         </a>
         ]. Twenty-nine percent of the seroconversions occurred periconceptionally or in the first trimester, thereby placing the subsequent fetus at risk of sequelae from primary maternal CMV infection.
        </p>
        <p class="headingAnchor" id="H744845589">
         <span class="h2">
          Maternal clinical findings
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Primary infection
         </strong>
         – Primary CMV infection is asymptomatic in approximately 90 percent of those infected. In the remaining 10 percent, clinical manifestations may include fever, rhinitis, pharyngitis, myalgia, arthralgia, headache, and/or fatigue.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The most common presentation of symptomatic CMV infection in immunocompetent adults is a syndrome resembling infectious mononucleosis, characterized by significant, often protracted fevers and lassitude in the setting of absolute lymphocytosis and atypical lymphocytes. (See
         <a class="medical medical_review" href="/z/d/html/8289.html" rel="external">
          "Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent adults", section on 'CMV mononucleosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8289.html" rel="external">
          "Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent adults", section on 'Organ-specific complications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Pregnancy does not appear to affect the clinical severity of primary CMV infection, but the integrity of the host immune system affects the spectrum of disease. Hosts with impaired cellular immunity are at risk for severe and disseminated infection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nonprimary infection
         </strong>
         – Reinfection with a different CMV strain or reactivation of virus in pregnant individuals with preexisting antibody is generally asymptomatic in the mother [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The clinical manifestations of CMV infection in adults are discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/8289.html" rel="external">
          "Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3509084523">
         <span class="h2">
          Role of maternal screening
         </span>
         <span class="headingEndMark">
          —
         </span>
         No professional societies or government health authorities recommend universal serological screening for recent CMV infection for the general obstetric population [
         <a href="#rid31">
          31
         </a>
         ]. Some authorities recommend targeted screening of pregnant people at increased risk of exposure, such as those with close contact with young children.
        </p>
        <p>
         The rationale
         <strong>
          against
         </strong>
         routine universal screening includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No vaccine is available to prevent infection in seronegative individuals.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Seropositive patients remain at risk of fetal infection from reactivation of latent virus and/or reinfection with a new viral strain.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Although fetal infection may occasionally be detected, whether the infected fetus will develop significant sequelae cannot be determined reliably.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Routine screening can lead to unnecessary, and potentially harmful, consequences, such as increased parental anxiety, unnecessary medical interventions, and increased terminations of pregnancy among those at low risk of CMV complications.
        </p>
        <p>
        </p>
        <p>
         In an observational study of over 75,000 pregnant individuals in Israel who underwent prenatal immunoglobulin M (IgM) screening for CMV infection, approximately one percent had a positive test [
         <a href="#rid32">
          32
         </a>
         ]. Among these patients, only one quarter underwent amniocentesis and those who did not undergo amniocentesis were more likely to terminate the pregnancy than those who underwent amniocentesis (35.6 versus 7.3 percent). Even those at low or moderate risk of intrauterine CMV transmission had termination rates of 19.2 and 23.6 percent, respectively, which greatly exceed the expected rates of affected fetuses/children. A 2020 cost-effectiveness analysis of serological screening in France concluded that routine screening would increase poor newborn outcomes 1.66-fold (mostly related to increased pregnancy terminations) without a corresponding decrease in severely symptomatic newborns [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In seropositive pregnant patients, it is difficult to distinguish between primary and nonprimary infection or determine the timing of the infection, which could have occurred many months before conception.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In seronegative pregnant patients, seroconversion can occur at any time. Repeated serologic screening during pregnancy is not commonly performed but does occur on an ad hoc basis in some countries such as Israel.
        </p>
        <p>
        </p>
        <p>
         The rationale
         <strong>
          for
         </strong>
         routine universal screening is:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Individuals who know they are seronegative and thus at risk of primary infection may adhere better to recommended hygiene measures, which might decrease the risk of seroconversion during pregnancy. (See
         <a class="local">
          'Behavioral risk reduction interventions'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Emerging evidence from randomized trials of the efficacy of maternal antiviral drug treatment of primary infection for prevention of fetal CMV infection [
         <a href="#rid34">
          34
         </a>
         ]. If these promising findings (described below) are replicated on a large scale, this intervention could be offered within a prenatal serological screening program. A 2023 cost-effectiveness analysis of serological screening strategies in France concluded that universal screening in conjunction with
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         treatment of patients with first-trimester primary CMV infection would be cost-effective [
         <a href="#rid35">
          35
         </a>
         ]. (See
         <a class="local">
          'Antiviral medication'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3187466925">
         <span class="h2">
          Candidates for documentation of baseline CMV serology
         </span>
         <span class="headingEndMark">
          —
         </span>
         In our practice, we obtain baseline CMV serology in pregnant patients at increased risk of undergoing diagnostic testing later in pregnancy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with a known high-risk exposure (mucosal exposure to known infected body fluids), we obtain baseline IgG and IgM CMV serology and, if negative, we repeat the tests three to four weeks later to assess for seroconversion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients infected with HIV, we obtain baseline IgG and IgM CMV serology at the first prenatal visit. This facilitates diagnostic testing for CMV in high-risk patients who develop signs/symptoms suggestive of CMV infection or have suggestive fetal ultrasound findings. (See
         <a class="local">
          'Diagnosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients who are immunosuppressed for other reasons (eg, on medication for organ transplant management), we individualize decision-making.
        </p>
        <p>
        </p>
        <p>
         Prepregnancy or early pregnancy baseline CMV IgG may be considered for individuals who are at high risk of infection. Early determination of CMV serostatus may aid in distinguishing between primary infection and reactivation/reinfection during pregnancy if clinically indicated, but does not remove the need to follow recommended hygiene measures.
        </p>
        <p class="headingAnchor" id="H3455424008">
         <span class="h2">
          Diagnosis
         </span>
        </p>
        <p class="headingAnchor" id="H1003166778">
         <span class="h3">
          When to suspect maternal CMV infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Maternal CMV infection should be suspected and testing performed in the following individuals [
         <a href="#rid36">
          36
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnant patients with mononucleosis-like or influenza-like illness, especially in the setting of negative Epstein-Barr and influenza virus tests. (See
         <a class="medical medical_review" href="/z/d/html/8318.html" rel="external">
          "Infectious mononucleosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7004.html" rel="external">
          "Seasonal influenza in adults: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnant patients with clinical manifestations of hepatitis (eg, fever, fatigue, loss of appetite, nausea, vomiting, abdominal pain, dark urine, light-colored stools, joint pain, jaundice) in the setting of negative viral hepatitis panel. (See
         <a class="medical medical_review" href="/z/d/html/3627.html" rel="external">
          "Hepatitis B virus: Clinical manifestations and natural history"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3680.html" rel="external">
          "Hepatitis B virus: Screening and diagnosis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnant patients in whom fetal ultrasound shows anomalies suggestive of congenital CMV infection (eg, periventricular calcifications, ventriculomegaly). (See
         <a class="local">
          'Ultrasound markers suggestive of congenital CMV infection'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1739744847">
         <span class="h3">
          Diagnosis of primary versus past maternal infection
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Seroconversion of CMV-specific IgG in paired acute and convalescent sera collected three to four weeks apart is diagnostic of a new acute infection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the absence of documented recent seroconversion, the diagnosis of primary CMV infection versus past infection is based on serology (IgG, IgM, and IgG avidity), as described in the table  (
         <a class="graphic graphic_table graphicRef110083" href="/z/d/graphic/110083.html" rel="external">
          table 1
         </a>
         ). Laboratory testing protocols vary. Most laboratories will perform IgG avidity testing if the patient is both CMV IgG and IgM positive, but whether avidity testing has to be specifically requested in this scenario or whether it occurs as a reflex test is subject to local procedures.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         IgM alone is not helpful for timing the onset of infection because (1) it is present in only 75 to 90 percent of individuals with acute infection, (2) it can remain positive for over one year after an acute infection, (3) it can revert from negative to positive in individuals with CMV reactivation or reinfection with a different strain, and (4) it can become positive in response to other viral infections, such as Epstein-Barr virus. Rising titers alone also are not diagnostic.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Because CMV-specific IgG may represent primary infection, reactivation, reinfection, or latent disease, determining IgG avidity is helpful for assessing the acuity of the infection and thus the risk of in utero transmission [
         <a href="#rid37">
          37-42
         </a>
         ]. High antibody avidity suggests infection occurred more than three months in the past, while low avidity suggests recent infection within three months. However, commercial avidity antibody assays have varying performance characteristics [
         <a href="#rid43">
          43
         </a>
         ], the interpretation of intermediate avidity and the optimal cutoffs for low and high avidity are not well established [
         <a href="#rid44">
          44,45
         </a>
         ], and the cutoffs for low and high avidity vary among laboratories.
        </p>
        <p>
        </p>
        <p>
         The diagnosis of CMV is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/8291.html" rel="external">
          "Overview of diagnostic tests for cytomegalovirus infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3207969906">
         <span class="h2">
          Prognostic counseling at the time of maternal diagnosis
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Frequency of fetal infection after seroconversion
         </strong>
         – Patients who seroconvert to CMV positive during pregnancy are at highest risk for maternal-fetal transmission and the frequency of vertical transmission increases with advancing gestational age at the time of seroconversion. In a review that pooled data from 10 studies of maternal-fetal CMV transmission in nearly 3000 patients who seroconverted just before or during pregnancy, the rates fetal infection were [
         <a href="#rid46">
          46
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Preconception period (up to 12 weeks before the last menstrual period) – 5.5 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Periconceptional period (four weeks before to six weeks after the last menstrual period) – 21.0 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         First trimester – 36.8 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Second trimester – 40.3 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Third trimester – 66.2 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Frequency of clinical sequelae after seroconversion
         </strong>
         – Although the frequency of vertical transmission increases with advancing gestational age, the frequency of clinical sequalae in the fetus/newborn decreases with advancing gestational age and clinical sequalae are unlikely when maternal infection occurs in the second half of pregnancy [
         <a href="#rid46">
          46-49
         </a>
         ]. In a review of pooled data from 10 studies (796 fetuses), the rates of clinical sequelae (neurologic symptoms at birth or termination of pregnancy because of CMV-associated findings in the central nervous system on ultrasonography or magnetic resonance imaging [MRI]) by gestational age of maternal seroconversion were [
         <a href="#rid46">
          46
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Periconceptional period (four weeks before to six weeks after the last menstrual period) – 28.8 percent (95% CI 2.4-55.1)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         First trimester – 19.3 percent (95% CI 12.2-26.4)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Second trimester – 0.9 percent (95% CI 0-2.4)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Third trimester – 0.4 percent (95% CI 0-1.5)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Frequency of fetal infection in patients with preconception CMV seroimmunity
         </strong>
         – Preconception seroimmunity provides substantial but not complete protection against the occurrence of fetal infection [
         <a href="#rid50">
          50
         </a>
         ]. The risk of fetal infection in this population is estimated to be about 1 percent (0.15 to 2 percent) [
         <a href="#rid7">
          7,20,25,47
         </a>
         ]. Since the seroimmune population is much larger than the population with documented seroconversion during pregnancy, 75 percent of congenitally-infected infants in the United States have been attributed to nonprimary maternal infection [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Pregnant patients with HIV appear to be an exception to the observation that frequency of fetal infection is low among seropositive pregnant patients. Advanced maternal immunocompromise has been associated with a higher birth prevalence of congenital CMV infection, despite maternal antiretroviral prophylaxis [
         <a href="#rid8">
          8,52-55
         </a>
         ]. A study from the United States reported congenital CMV rates remained high in HIV-exposed but uninfected infants born during the era of antiretroviral therapy [
         <a href="#rid56">
          56
         </a>
         ], whereas a French study reported congenital CMV prevalence decreased in infants born to mothers on antiretroviral therapy [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1858307305">
         <span class="h2">
          Maternal care
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to routine prenatal care, immunocompetent pregnant patients with symptomatic CMV infection should be offered supportive care for symptomatic relief, as needed (eg,
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         for fever). Use of antiviral drugs for maternal treatment of CMV infections in immunocompetent adults, including pregnant patients, is rarely indicated. Several medications (eg,
         <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">
          ganciclovir
         </a>
         ,
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         ,
         <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">
          cidofovir
         </a>
         ) are available to treat severe end-organ CMV disease in nonpregnant adults but experience in pregnancy is limited. Maternal treatment is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/8289.html" rel="external">
          "Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent adults", section on 'Therapy'
         </a>
         .)
        </p>
        <p>
         Pregnant patients with
         <strong>
         </strong>
         suspected CMV infection often experience uncertainty, anxiety, and stress, which can be exacerbated by their health care professional's lack of knowledge and lack of patient information [
         <a href="#rid58">
          58
         </a>
         ]. Patients and families should be offered well-informed counselling and support following a suspected/confirmed diagnosis of congenital CMV. Referral to a maternal-fetal medicine specialist can be useful. Consumer-led support groups are available in a growing number of countries and include the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nationalcmv.org%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2FwA%2B5Z7ybrabseqa831%2BsMRJ0HcNj1XANifTskWjj%2FW%2F&amp;TOPIC_ID=4810" target="_blank">
          National CMV Foundation
         </a>
         (United States),
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fcmvcanada.com%2F&amp;token=xv9UpyQjV5vRDEb2mf7jyda9xQIVcaQAbveM78v4Wqo%3D&amp;TOPIC_ID=4810" target="_blank">
          CMV Canada
         </a>
         , , and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cmv.org.au%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlOl3FhNkSwp90c909VGTQX8%3D&amp;TOPIC_ID=4810" target="_blank">
          CMV Australia
         </a>
         .
        </p>
        <p class="headingAnchor" id="H2130888644">
         <span class="h1">
          FETAL ISSUES
         </span>
        </p>
        <p class="headingAnchor" id="H537791906">
         <span class="h2">
          Ultrasound markers suggestive of congenital CMV infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following ultrasonographic markers are suggestive, but not diagnostic, of fetal CMV infection [
         <a href="#rid3">
          3,59-67
         </a>
         ]. The abnormalities can appear 12 or more weeks after maternal infection [
         <a href="#rid67">
          67,68
         </a>
         ]. Some infected fetuses do not develop ultrasound abnormalities.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Periventricular calcifications  (
         <a class="graphic graphic_diagnosticimage graphicRef54305" href="/z/d/graphic/54305.html" rel="external">
          image 1
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cerebral ventriculomegaly  (
         <a class="graphic graphic_diagnosticimage graphicRef98824" href="/z/d/graphic/98824.html" rel="external">
          image 2
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Microcephaly
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pseudocysts, periventricular or adjacent to the occipital or temporal horn
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyperechogenic fetal bowel  (
         <a class="graphic graphic_diagnosticimage graphicRef73631" href="/z/d/graphic/73631.html" rel="external">
          image 3
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fetal growth restriction
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ascites  (
         <a class="graphic graphic_diagnosticimage graphicRef56150" href="/z/d/graphic/56150.html" rel="external">
          image 4
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pleural and/or pericardial effusion  (
         <a class="graphic graphic_diagnosticimage graphicRef56150" href="/z/d/graphic/56150.html" rel="external">
          image 4
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef54321" href="/z/d/graphic/54321.html" rel="external">
          image 5
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatosplenomegaly
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatic calcifications
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Polymicrogyria
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cerebellar hypoplasia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Large cisterna magna
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Amniotic fluid abnormalities (oligohydramnios or polyhydramnios)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hydrops
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Placental thickening and enlargement, heterogeneous appearance, calcifications
        </p>
        <p>
        </p>
        <p>
         The most characteristic sonographic finding of fetal CMV infection is bilateral periventricular hyperechogenicities (calcifications)  (
         <a class="graphic graphic_diagnosticimage graphicRef54305" href="/z/d/graphic/54305.html" rel="external">
          image 1
         </a>
         ) [
         <a href="#rid69">
          69,70
         </a>
         ]. These calcifications or hyperechoic foci can be highly reflective and may not cast an acoustic shadow [
         <a href="#rid71">
          71
         </a>
         ]. Branching linear echogenic areas in the thalami also occur and correspond to arteries in the basal ganglia and thalamus [
         <a href="#rid72">
          72,73
         </a>
         ]. The presence of intraventricular filmy, thin adhesions and linear edges traversing the ventricle is typical in CMV infection of the brain [
         <a href="#rid65">
          65,74-82
         </a>
         ].
        </p>
        <p>
         Although there is a considerable overlap in imaging findings between congenital CMV infection and congenital Zika syndrome, severe microcephaly, evidence of fetal brain collapse (fetal brain disruption sequence), and contractures are most characteristic of fetal Zika virus infection [
         <a href="#rid83">
          83
         </a>
         ]. In addition, the distribution of intracerebral calcifications is subcortical in congenital Zika syndrome but periventricular in congenital CMV infection.
        </p>
        <p>
         Late-onset isolated fetal growth restriction is unlikely to be related to CMV. A systematic review investigating the yield of maternal TORCH serology for fetal ultrasound abnormalities found that the rate of congenital CMV among infants with isolated late-onset growth restriction was 0.4 percent (2 out of 496) [
         <a href="#rid84">
          84
         </a>
         ], while a multicenter cohort study of fetuses with late-onset fetal growth restriction reported a congenital CMV rate of rate of 0.2 percent (3 out of 1246) [
         <a href="#rid85">
          85
         </a>
         ]. These rates are similar to the birth prevalence of CMV in high-income countries. For this reason, the Society for Maternal-Fetal Medicine in the US states that routine CMV serology may not be warranted for the investigation of fetal growth restriction in the absence of risk factors or ultrasound markers of fetal infection [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4044995989">
         <span class="h2">
          Diagnosis of fetal infection
         </span>
        </p>
        <p class="headingAnchor" id="H617333199">
         <span class="h3">
          Diagnosis
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fetal CMV infection should be suspected in patients with maternal serology consistent with a primary infection or ultrasound findings (other than isolated growth restriction) suggestive of congenital infection. (See
         <a class="local">
          'Diagnosis'
         </a>
         above and
         <a class="local">
          'Ultrasound markers suggestive of congenital CMV infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, maternal serology for CMV infection is of limited clinical utility when investigating fetal ultrasound abnormalities in the second or third trimester. Although the combination of CMV IgG- and IgM-negative results exclude CMV as a cause of the ultrasound finding, the combination of a CMV IgG-positive result and a CMV IgM-negative result after 16 weeks does not because this serology result could still occur following maternal primary or nonprimary first-trimester infection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The diagnosis of fetal infection is confirmed in pregnancies by positive polymerase chain reaction (PCR) for CMV DNA in amniotic fluid; sensitivity ranges from 70 to 100 percent [
         <a href="#rid59">
          59-61,68,87
         </a>
         ]. Viral culture is less desirable because of several limitations, discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8291.html" rel="external">
          "Overview of diagnostic tests for cytomegalovirus infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2424377077">
         <span class="h3">
          Diagnostic amniocentesis
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Candidates and rationale
         </strong>
         – We offer amniocentesis for prenatal (fetal) diagnosis when fetal infection is suspected based on maternal serology consistent with a primary infection or ultrasound findings are suggestive of congenital infection. (See
         <a class="local">
          'Diagnosis'
         </a>
         above and
         <a class="local">
          'Ultrasound markers suggestive of congenital CMV infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The rationale for offering prenatal diagnosis is that the frequency of fetal infection after a maternal primary infection ranges from 36.8 to 66.2 percent [
         <a href="#rid46">
          46
         </a>
         ] and ultrasound findings are not reliable for diagnosing fetal CMV infection. Some parents may use this information in decision-making regarding termination of pregnancy. It helps others prepare for the birth of an infected and possibly clinically affected child (see
         <a class="medical medical_review" href="/z/d/html/14430.html" rel="external">
          "Congenital cytomegalovirus infection: Clinical features and diagnosis"
         </a>
         ). In addition, knowing that the fetus is infected may change ongoing fetal surveillance (eg, frequency of ultrasound examination, offer of fetal brain MRI), is informative for the pediatricians caring for the child, and may prompt selective use of maternal antiviral therapy to reduce fetal infection and/or clinical sequelae. (See
         <a class="local">
          'Maternal treatment for fetal benefit'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a prospective study of 55 amniocentesis procedures performed for maternal primary CMV infection before 24 weeks, results were positive for CMV in 25 percent [
         <a href="#rid88">
          88
         </a>
         ]. The neonates of all 12 subjects with a positive amniocentesis and available results had CMV confirmed after birth, as did 2 neonates from 41 subjects with a negative amniocentesis, resulting in sensitivity 86 percent (95% CI 57-98), specificity 100 percent (95% CI 91-100), positive predictive value 100 percent (95% 74-100), and negative predictive value 95 percent (95% CI 83-99).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Timing
         </strong>
         – In patients with a primary CMV infection, an interval of at least eight weeks between diagnosis and amniocentesis is desirable for high diagnostic sensitivity, since it takes six to eight weeks for placental infection and replication, transmission to the fetus, viral replication in the fetal kidney, and excretion into amniotic fluid [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Traditionally, sensitivity has been reported to be highest after 21 weeks of gestation; however, emerging data suggest that an interval of eight weeks following maternal primary infection is a more appropriate benchmark.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a prospective study of maternal
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         treatment for secondary prevention of fetal infection, amniocentesis for diagnosis of fetal infection performed at 17 to 20 weeks and at least 8 weeks from maternal primary infection had sensitivity 95.8 percent (95% CI 79.8-99.8 percent), specificity 100 percent (95% CI 91.8-100.0), positive predictive value 100 percent (95% CI 85.7-100.0) and a negative predictive value 97.7 percent (95% CI 88.2-99.9) [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a retrospective study that reviewed 264 pregnancies at 17 to 23 weeks of gestation with at least 8 weeks between seroconversion and amniocentesis, diagnostic sensitivity was similar before versus after 21 weeks (87.2 and 92.1 percent, respectively), as was negative predictive value (93.6 and 96.8 percent, respectively) [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Procedure
         </strong>
         – The first 1 mL of fluid obtained should be discarded to reduce the risk of maternal cell contamination [
         <a href="#rid59">
          59-61,90
         </a>
         ]. Rarely, false-positive results occur from contamination of the amniotic fluid sample by maternal fluids. (See
         <a class="medical medical_review" href="/z/d/html/5390.html" rel="external">
          "Diagnostic amniocentesis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         CMV DNA in maternal blood at the time of amniocentesis does not appear to be a significant risk factor for iatrogenic antepartum transmission [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3835082880">
         <span class="h2">
          Predicting outcome after confirmation of fetal infection
         </span>
        </p>
        <p class="headingAnchor" id="H1494141423">
         <span class="h3">
          Primary versus nonprimary maternal infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although fetal infection is less likely in individuals with seroimmunity [
         <a href="#rid20">
          20
         </a>
         ], when it occurs, the frequency of symptomatic newborn disease and long-term sequelae is similar to that of offspring of mothers with primary CMV infection during pregnancy [
         <a href="#rid92">
          92
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4128717072">
         <span class="h3">
          Normal versus abnormal ultrasound findings
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Normal ultrasound examination
         </strong>
         – A normal ultrasound examination is reassuring but does not completely exclude the possibility of a symptomatic neonate or development of long-term neurologic morbidity. Serial ultrasound examinations at two- to four-week intervals can be useful to detect development of sonographic abnormalities, which can appear 12 or more weeks after a periconceptional or early pregnancy maternal infection, or not at all [
         <a href="#rid67">
          67,68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a systematic review including 1178 fetuses with a normal ultrasound examination at the time of maternal diagnosis of CMV infection, [
         <a href="#rid93">
          93
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         An associated CNS anomaly was detected on follow-up ultrasound in 4.4 percent of cases (95% CI, 1.4-8.8 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         An associated extra-CNS anomaly was detected on follow-up ultrasound in 2.9 percent of cases (95% CI, 0.8-6.3 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Symptomatic infection occurred in 1.5 percent of cases (95% CI, 0.7-2.7 percent), and the overall rate of a neurodevelopmental anomaly in these cases was 3.1 percent (95% CI, 1.6-5.1 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hearing problems affected 6.5 percent of children (95% CI 3.8-10 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Motor and cognitive delays and visual problems occurred in 2.3, 1.1, and 1 percent of children, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Importantly, when trimester of primary maternal infection was considered:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         An anomaly was subsequently detected only among fetuses infected in the first trimester.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Abnormal childhood neurodevelopment outcome only occurred among fetuses infected in the first trimester, and the rate was 5.4 percent in this group.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hearing problems occurred in 11.4 percent of children infected in the first trimester, 7 percent of those infected in the second trimester, and none of those infected in the third trimester.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Abnormal ultrasound
         </strong>
         – Fetal abnormalities, such as ventriculomegaly, periventricular calcifications, microcephaly, growth restriction, and hydrops, suggest severe disease and a high risk of long-term neurodevelopmental impairment. (See
         <a class="medical medical_review" href="/z/d/html/98188.html" rel="external">
          "Congenital cytomegalovirus infection: Management and outcome", section on 'Outcome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Of note, there are no fetal imaging findings (ultrasound or MRI) specifically predictive of postnatal hearing loss.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2724776049">
         <span class="h3">
          Other tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         None of the following tests are useful routinely. All provide information about the status of the fetus at the time of the test, but none substantially improves prediction of a normal versus abnormal neurodevelopmental outcome compared with ultrasound alone.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Viral load in amniotic fluid
         </strong>
         – The prognostic value of CMV viral load in amniotic fluid has been studied as a possible predictor of symptomatic disease at birth for fetuses with normal ultrasound [
         <a href="#rid3">
          3,94-96
         </a>
         ]. One study found that a viral load &gt;100,000 copies/mL of amniotic fluid at weeks 21 to 23 of gestation distinguished the seven fetuses/newborns with signs and/or symptoms of congenital CMV infection from the 16 who appeared normal and asymptomatic [
         <a href="#rid94">
          94
         </a>
         ]. Another retrospective study calculated a negative predictive value for symptoms at birth or at termination of pregnancy of 93 percent for ultrasound alone versus 95 percent for ultrasound and viral load in amniotic fluid [
         <a href="#rid96">
          96
         </a>
         ]. However, the viral load threshold for predicting symptoms at birth has not been robustly defined or validated in independent prospective cohorts.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          MRI
         </strong>
         – The value of MRI after a normal neurosonogram by an expert sonologist is unclear. If an abnormality is suspected on ultrasound and clarification is needed, MRI may be helpful. The cost of the additional imaging and likelihood of gaining information that will alter management should be considered.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a systematic review, MRI detected a central nervous system anomaly after a normal ultrasound in approximately 6 percent of fetuses with CMV [
         <a href="#rid93">
          93
         </a>
         ]. Nevertheless, detection of subtle nonprogressive findings on MRI are not necessarily predictive of neurodevelopmental impairment, particularly when the ultrasound is normal [
         <a href="#rid97">
          97
         </a>
         ]. In addition, although the combination of normal fetal ultrasound and normal MRI had a high negative predictive value in another systematic review [
         <a href="#rid98">
          98
         </a>
         ], these findings do not completely exclude the possibility of development of postnatal hearing loss, a common sequelae of congenital CMV infection [
         <a href="#rid67">
          67,99
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fetal blood sampling
         </strong>
         – Cordocentesis for evaluation of fetal CMV disease is not recommended. Abnormal liver function tests, hematologic tests (especially thrombocytopenia), and beta-2 microglobulin level are signs of severe disease, but this information is not substantially more predictive of an unfavorable long-term outcome than an abnormal ultrasound, and cordocentesis is associated with a 2 percent risk of procedure-related fetal loss [
         <a href="#rid96">
          96,100,101
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5389.html" rel="external">
          "Fetal blood sampling", section on 'Complications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1876578532">
         <span class="h1">
          DELIVERY AND NEWBORN CARE
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Timing and route of birth
         </strong>
         – The timing and route of birth are determined by standard obstetric indications. Recovery of CMV from the cervix or urine is not an indication for cesarean birth.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Newborn care
         </strong>
         – Newborns considered to be at increased risk of congenital CMV infection because of ultrasound or placental findings or maternal history should be tested within the first 21 days of life even if a prior diagnostic amniocentesis was negative because at least 8 percent of such newborns have detectable CMV at birth after a negative amniocentesis [
         <a href="#rid102">
          102
         </a>
         ]. These neonates appear to be at extremely low risk of long-term sequalae, but should be offered regular hearing and vision screening in accordance with local clinical guidelines [
         <a href="#rid103">
          103
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14430.html" rel="external">
          "Congenital cytomegalovirus infection: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/98188.html" rel="external">
          "Congenital cytomegalovirus infection: Management and outcome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Breastfeeding
         </strong>
         – Although CMV can be transmitted through breast milk, the demonstrated benefits of breastfeeding probably outweigh the minimal risk to a healthy term newborn from acquiring CMV from individual actively shedding CMV. However, we advise consultation with the pediatric provider if a lactating individual with active CMV viral shedding desires to provide breastmilk to a preterm or unwell neonate [
         <a href="#rid104">
          104-106
         </a>
         ]. Treatment of breast milk by freezing/thawing or pasteurization can reduce or prevent transmission of CMV. (See
         <a class="medical medical_review" href="/z/d/html/5965.html" rel="external">
          "Overview of cytomegalovirus infections in children", section on 'Prevention of neonatal transmission'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         HIV-infected mothers in areas where formula is readily available are advised to not breastfeed because of a possible risk of HIV transmission. (See
         <a class="medical medical_review" href="/z/d/html/13972.html" rel="external">
          "Prenatal evaluation of women with HIV in resource-rich settings", section on 'Counseling'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Placental pathology
         </strong>
         – The classic histopathologic placental findings associated with CMV infection include the following, although not all may be present:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lymphoplasmacytic villitis (diffuse chronic villitis with plasma cells)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sclerosis of the villous capillaries
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chorionic vessel thromboses
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Necrotizing villitis
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hemosiderin deposition in the villous stroma
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Normoblastemia
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         CMV replication has been demonstrated in smooth muscle cells of arteries and veins in floating villi and the chorion [
         <a href="#rid107">
          107
         </a>
         ]. Large fibrinoids with many avascular villi and edematous villi and inflammation, changes that likely impair placental transport, have been observed in births complicated by intrauterine growth restriction and primary or nonprimary CMV infection. Progressive fetal thrombotic vasculopathy has been observed in stillbirths.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Viral inclusions  (
         <a class="graphic graphic_picture graphicRef70713" href="/z/d/graphic/70713.html" rel="external">
          picture 1
         </a>
         ), which can be subtle, are observed in 10 percent of cases in fetal infection but are more often visible in cases associated with stillbirth. Immunohistochemistry may detect many inclusions not identified with routine hematoxylin-eosin stains [
         <a href="#rid108">
          108
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          STRATEGIES FOR PREVENTION OF MATERNAL AND/OR FETAL INFECTION
         </span>
        </p>
        <p class="headingAnchor" id="H3431986064">
         <span class="h2">
          Behavioral risk reduction interventions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although no actions can eliminate all risks of becoming infected with CMV, seroconversion rates may be reduced by preventive behavioral interventions [
         <a href="#rid62">
          62,109-113
         </a>
         ]. In one study of patients who were seronegative at 11 to 12 weeks of gestation, seroconversion occurred in 1.2 percent of those who received specific hygiene information and were prospectively tested for CMV until delivery [
         <a href="#rid111">
          111
         </a>
         ]. By comparison, seroconversion occurred in 7.6 percent of patients enrolled at delivery who were neither tested for nor informed about CMV during pregnancy, and who had a serum sample stored at the time of fetal aneuploidy screening. However, in at least one study, risk reduction information did not significantly affect seroconversion rates in nonpregnant females, even in those trying to conceive [
         <a href="#rid110">
          110
         </a>
         ]. While these data are from low-quality studies, hygiene advice for people in early pregnancy or trying to conceive is reasonable based on the known methods of transmission.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Counseling for all pregnant individuals
         </strong>
         – Practice good personal hygiene throughout pregnancy, especially after contact with body fluids from young children. This includes:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hand washing with soap and water after changing diapers or wiping a child's nasal secretions or saliva.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Avoiding getting a child's saliva in your mouth. Suggested risk-reducing behaviors include not sharing food, utensils, or cups with a child, and kissing children on the forehead instead of the lips.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Counseling health care workers
         </strong>
         – The risk of CMV infection among health care workers appears to be no greater than that among the general public. This is probably due, at least in part, to adherence to standard precautions by health care providers when handling body fluids and less personal contact in the health care setting than in the family setting.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Counseling females about timing of conception after recent primary CMV infection
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Because CMV DNA has been detected in blood of 20 percent of immunocompetent patients as long as six months after diagnosis of primary infection, some experts suggest that an individual wait at least six months after a primary infection before attempting to conceive; however, data on the risk of congenital CMV in nonprimary maternal infection are limited [
         <a href="#rid3">
          3
         </a>
         ]. Others suggest waiting a minimum of three or four months and/or documenting the presence of high-avidity CMV IgG antibodies before attempting to conceive [
         <a href="#rid114">
          114
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The use of high-dose
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         during pregnancy may delay the maternal adaptive immune response to CMV. One case of severe fetal CMV infection has been reported in an immunocompetent pregnant patient treated with valacyclovir during their first affected pregnancy [
         <a href="#rid115">
          115
         </a>
         ]. The patient conceived 10 weeks after cessation of valacyclovir treatment and had high-avidity IgG antibodies. The subsequent pregnancy was infected by the same strain of CMV. Pregnancy termination was performed because of severe fetal sequalae. The authors suggest that a longer interval between pregnancies should be advised if a patient has been treated with valacyclovir during the prior pregnancy. Further research is needed to determine if valacyclovir alters the natural history of maternal immunity and the risk of congenital CMV in nonprimary maternal infection.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3474235283">
         <span class="h2">
          Use of CMV-negative blood when transfusion is indicated
         </span>
         <span class="headingEndMark">
          —
         </span>
         CMV-seronegative pregnant individuals, fetuses, and newborns should be transfused, when necessary, with blood from CMV-seronegative donors. (See
         <a class="medical medical_review" href="/z/d/html/7939.html" rel="external">
          "Practical aspects of red blood cell transfusion in adults: Storage, processing, modifications, and infusion", section on 'Specialized modifications and products'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H922764953">
         <span class="h2">
          Maternal treatment for fetal benefit
         </span>
        </p>
        <p class="headingAnchor" id="H509499980">
         <span class="h3">
          Antiviral medication
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest high-dose
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         to patients who have a primary CMV infection during early pregnancy, after a comprehensive discussion of the potential benefits and risks. While increasing evidence (discussed below) supports the potential benefit of maternal antiviral therapy for reducing fetal infection in those with primary CMV infection during early pregnancy, it is not a routine treatment as only limited data are available on maternal, perinatal and long-term outcomes and serious maternal toxicity is possible (reversible kidney failure in approximately 2 percent patients [
         <a href="#rid111">
          111,116
         </a>
         ]) [
         <a href="#rid115">
          115
         </a>
         ]. Most patients have been treated as part of a research study. If used outside of a clinical trial, we strongly recommend monitoring and reporting maternal and infant outcomes, with periodic review to ensure that the intervention is safe, effective, appropriately integrated into prenatal care, and continuously improved based on accumulating data. (See
         <a class="medical medical_review" href="/z/d/html/8337.html" rel="external">
          "Valacyclovir: An overview", section on 'Toxicity'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evidence for preventing vertical transmission
         </strong>
         – Secondary prevention strategies involving antiviral therapy for preventing vertical transmission are challenging given that most maternal infections are asymptomatic and screening for CMV is not routinely performed. However, for those who are identified as having a primary infection in early pregnancy,
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         is an option, with the above caveats regarding monitoring for side effects and maternal and perinatal outcomes.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The highest-quality evidence for
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         treatment to reduce fetal infection comes from a double-blinded randomized trial in which 100 pregnant people with serological evidence of first-trimester or periconception (four weeks before to three weeks after the last menstrual period) primary CMV infection were administered oral valacyclovir (8 g daily in two to four doses) or placebo prior to 14 weeks gestation [
         <a href="#rid117">
          117
         </a>
         ]. The intervention reduced the rate of CMV-positive amniotic fluid in amniocentesis performed at &gt;21 weeks gestation (30 versus 11 percent; OR 0.29, 95% CI 0.09-0.90). When stratified by timing of maternal infection, a significant treatment effect was observed in the first-trimester infection group (48 versus 11 percent), but not the periconception group (12 versus 13 percent). This discrepancy was presumed to be due to the later initiation of treatment in those with primary periconception infection. For the three fetal infections in the valacyclovir treated periconception group, the time interval between periconception infection and initiation of treatment was 10, 12, and 14 weeks, respectively. However, the overall rate of congenital CMV infection was not different between the two groups. Although participants in valacyclovir group had a lower risk of adverse outcomes, the duration of follow-up of infected children to monitor outcomes was not clear.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The authors subsequently revised their protocol to begin antiviral treatment earlier (up to nine weeks from the assumed time of periconception infection or up to eight weeks from the assumed time of first-trimester infection) and found that earlier initiation of
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         was associated with significantly larger treatment effects in an observational study [
         <a href="#rid118">
          118
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a 2023 individual patient data meta-analysis of one randomized trial (described above) and two observational studies (total 527 participants), maternal
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         therapy of periconceptional or first trimester primary CMV infection was associated with reduced [
         <a href="#rid34">
          34
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Vertical transmission (11.1 versus 25.5 percent; adjusted odds ratio [aOR] 0.34, 95% CI 0.18-0.61).
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Neonatal infection (19.2 versus 41.1 percent; aOR 0.30, 95% CI 0.19-0.47)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Termination of pregnancy due to CMV-associated severe fetal abnormalities (0.9 versus 4.5 percent; aOR 0.23, 95% CI 0.22-0.24).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The reductions in vertical transmission and neonatal infection were similar for periconception and first-trimester infections.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Earlier treatment initiation improved prevention rates. The number needed to treat to prevent a positive CMV amniocentesis was 6.9. Severe maternal side effects occurred in 2.1 percent and consisted of acute obstructive kidney failure, which may occur because of deposition of crystalline byproduct in the kidney and may be minimized by volume repletion [
         <a href="#rid102">
          102,119
         </a>
         ]. On GRADE assessment, the quality of evidence that
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         can reduce the risk of congenital CMV infection and adverse perinatal outcomes was very low.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Italy has added
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         therapy for the secondary prevention of congenital CMV to its national medicines reimbursement system. A multicenter observational study from Italy (MEGAL-ITALI) including 447 pregnant people (205 treated with valacyclovir, 242 untreated) reported treatment was associated with statistically significant reductions in CMV diagnosis at amniocentesis and in the composite outcome of "termination of pregnancy or diagnosis of congenital CMV at birth" (24.7 versus 34.4 percent) [
         <a href="#rid120">
          120
         </a>
         ]. Of note, however, the rate of congenital CMV at birth was higher in the treated group (15.5 versus 6.7 percent), though most were asymptomatic. The authors concluded that the use of valacyclovir likely modifies the disease course and produces a rebound viremia after treatment cessation and fetal infection after a negative amniocentesis. While previous reports provide reassurance regarding the low risk of significant sequalae following second- or third-trimester fetal CMV infection, these data come from patients who did not receive valacyclovir [
         <a href="#rid102">
          102
         </a>
         ]. Long-term follow-up of newborns with asymptomatic congenital CMV after prenatal valacyclovir therapy is essential to fully understand the impact of antiviral treatment during pregnancy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evidence for improving the outcome of infected fetuses
         </strong>
         – Maternal
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         administration has also been used for tertiary prevention of complications in infected fetuses. In a 2023 meta-analysis, although infected pregnant people treated with valacyclovir had a reduction in congenital CMV infection and an increased likelihood that the infection would be asymptomatic, there was no improvement in any other CMV-related perinatal outcome (eg, perinatal death, neurological symptoms, hearing symptoms, anomalies on follow-up prenatal or postnatal imaging) [
         <a href="#rid116">
          116
         </a>
         ]. However, the number of adverse neonatal outcomes was low and confidence intervals were wide, highlighting the need for validation of the findings in large, well-designed randomized trials.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         One study not included in the meta-analysis has reported promising findings in a subset of infected fetuses with ultrasound abnormalities. In this multicenter, open-label, phase II study of oral
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         administration to pregnant patients carrying a CMV-infected fetus with an isolated nonsevere cerebral abnormality and/or measurable extracerebral findings compatible with CMV infection, maternal treatment improved neonatal outcome [
         <a href="#rid121">
          121
         </a>
         ]. Fetuses with severe brain anomalies and those with no abnormalities at presentation were excluded from the study because treatment was unlikely to modify outcome in these fetuses. Compared with a historical cohort obtained by a meta-analysis, the use of valacyclovir increased the proportion of asymptomatic neonates from 43 percent without treatment to 82 percent with treatment, and asymptomatic neonates remained asymptomatic at 12 months postnatal age. Valacyclovir 8 g daily was initiated at a median of 25.9 weeks of gestation and continued until delivery or termination of pregnancy. Adherence to treatment was &gt;90 percent despite the need to take 16 pills/day, and there was a low rate of discontinuation due to maternal side effects (2 out of 41 patients reported headaches, treatment was suspended for 10 days in one). However, the findings are limited by the open-label study design and should be confirmed in a randomized trial to better determine the efficacy of in utero treatment before it can be recommended. Long-term pediatric follow-up is also needed.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3136274955">
         <span class="h3">
          Other agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         CMV-specific hyperimmune globulin therapy of pregnant patients with primary CMV infection in early pregnancy is not recommended. This investigational approach was ineffective in two randomized trials that initiated immunoglobulin therapy in the second trimester (no reduction in congenital infection, death, preterm birth, symptomatic infection) [
         <a href="#rid28">
          28,122
         </a>
         ]. One of the trials with long-term follow-up found that CMV hyperimmune globulin did not improve two-year hearing or developmental outcomes [
         <a href="#rid123">
          123
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Observational studies using biweekly first-trimester regimens for CMV hyperimmune immunoglobulin have had more promising results but need to be evaluated in a randomized trial [
         <a href="#rid124">
          124,125
         </a>
         ]. Given these mixed findings, CMV hyperimmune globulin therapy should only be used in research settings until more data are available.
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Development of a vaccine
         </span>
         <span class="headingEndMark">
          —
         </span>
         No CMV vaccine is available for use in humans, despite being ranked as the top priority for vaccine development by the Institute of Medicine in 1999 [
         <a href="#rid126">
          126
         </a>
         ]. Although several candidate vaccines have been developed and tested in clinical trials, it is unlikely that an effective CMV vaccine will be available for several years [
         <a href="#rid127">
          127-129
         </a>
         ]. One of the major barriers is the lack of an established maternal immune marker that indicates protection against transplacental CMV infection. Counterintuitively, CMV-neutralizing antibodies may not be relevant for protection against placental and fetal infection, and nonneutralizing antibodies involved in cellular phagocytosis may better correlate with prevention of congenital CMV [
         <a href="#rid130">
          130
         </a>
         ]. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109354.html" rel="external">
          "Society guideline links: Cytomegalovirus in solid organ transplant recipients"
         </a>
         .)
        </p>
        <p>
         In a phase 2 trial that included 464 CMV-seronegative females of childbearing age, an MF59-adjuvanted CMV glycoprotein B subunit vaccine had 50 percent efficacy at preventing CMV infection, which was the primary endpoint [
         <a href="#rid127">
          127
         </a>
         ]. The trial was not powered to assess efficacy in preventing maternal-fetal transmission. An international multicenter trial of a mRNA vaccine is currently underway in healthy (nonpregnant) adults in more than 10 countries and is expected to be completed in 2026 [
         <a href="#rid131">
          131
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H27542533">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/15831.html" rel="external">
          "Patient education: Avoiding infections in pregnancy (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/83958.html" rel="external">
          "Patient education: Cytomegalovirus (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/6717.html" rel="external">
          "Patient education: Avoiding infections in pregnancy (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/141878.html" rel="external">
          "Patient education: Cytomegalovirus infection and pregnancy (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Primary versus nonprimary infection
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Terminology
         </strong>
         – Cytomegalovirus (CMV) infections in pregnant individuals are classified as primary if the initial acquisition of virus occurs during pregnancy (seroconversion), and nonprimary if maternal antibody to CMV was present before conception (ie, seroimmunity). Nonprimary infection may be due to reactivation of latent virus or reinfection with a new strain. (See
         <a class="local">
          'Terminology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Sequelae of congenital infection
         </strong>
         – Clinical findings in symptomatic neonates are nonspecific and include petechiae, jaundice, hepatosplenomegaly, small size for gestational age, and microcephaly. Long-term sequelae include sensorineural hearing loss and other neurodevelopmental disabilities. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/14430.html" rel="external">
          "Congenital cytomegalovirus infection: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Risk for congenital infection
         </strong>
         – Primary maternal infection carries the highest risk for maternal-fetal transmission. The occurrence of congenital infection increases with advancing gestational age at the time of maternal diagnosis, while the occurrence of fetal/newborn complications from infection decreases with advancing gestational age at the time of maternal diagnosis. The risk of severe sequalae in offspring is high with first-trimester infection and very low with infection at or near term. (See
         <a class="local">
          'Prognostic counseling at the time of maternal diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Preconception seroimmunity provides substantial but not complete protection against the occurrence of congenital infection. When fetal infection occurs, the frequency of symptomatic newborn disease and long-term sequelae is similar to that of offspring of mothers with primary CMV infection during pregnancy. (See
         <a class="local">
          'Prognostic counseling at the time of maternal diagnosis'
         </a>
         above and
         <a class="local">
          'Primary versus nonprimary maternal infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Maternal clinical findings, screening, diagnosis, and treatment
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Clinical findings
         </strong>
         – CMV infection may cause a mild maternal febrile illness and other nonspecific symptoms but is asymptomatic in 90 percent of individuals. Maternal care is supportive. (See
         <a class="local">
          'Maternal clinical findings'
         </a>
         above and
         <a class="local">
          'Maternal care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Screening
         </strong>
         – No professional societies or government health authorities recommend universal serological screening for CMV infection for the general obstetric population. (See
         <a class="local">
          'Role of maternal screening'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Baseline serology
         </strong>
         – For those with a known exposure to CMV, we obtain baseline CMV serology at the time of the exposure and, if negative, we repeat the serology three to four weeks later to assess for seroconversion. We also obtain baseline CMV serology at the initial prenatal visit in patients infected with HIV. Prepregnancy or early pregnancy baseline CMV immunoglobulin G (IgG) may be considered for individuals who are at high risk of infection. Early determination of CMV serostatus may aid in distinguishing between primary infection and reactivation/reinfection during pregnancy if clinically indicated, but does not remove the need to follow recommended hygiene measures. (See
         <a class="local">
          'Candidates for documentation of baseline CMV serology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Indications for diagnostic testing
         </strong>
         – Diagnostic testing for CMV is indicated as part of the evaluation of individuals with mononucleosis-like illnesses or when a fetal anomaly consistent with congenital CMV infection is detected on prenatal ultrasound examination. (See
         <a class="local">
          'When to suspect maternal CMV infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Diagnosis
         </strong>
         – The gold standard for maternal diagnosis of clinically suspected primary CMV infection is IgG seroconversion  (
         <a class="graphic graphic_table graphicRef110083" href="/z/d/graphic/110083.html" rel="external">
          table 1
         </a>
         ). In the absence of documented seroconversion, the presence of anti-CMV IgG and anti-CMV immunoglobulin M (IgM) may represent primary infection, reactivation, reinfection, or latent disease. In these cases, IgG avidity testing is essential for interpretation: High-antibody avidity suggests infection occurred more than three months in the past, while low avidity suggests recent infection within three months. (See
         <a class="local">
          'Diagnosis of primary versus past maternal infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis of fetal infection
         </strong>
         –
         <strong>
         </strong>
         Fetal CMV infection should be suspected in patients with maternal serology consistent with a primary infection or ultrasound findings suggestive of congenital infection. (See
         <a class="local">
          'Diagnosis'
         </a>
         above and
         <a class="local">
          'Ultrasound markers suggestive of congenital CMV infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We offer amniocentesis for fetal diagnosis when fetal infection is suspected. The diagnosis of fetal infection is confirmed in pregnancies with positive polymerase chain reaction (PCR) for CMV DNA in amniotic fluid; sensitivity ranges from 70 to 100 percent. Amniocentesis should be performed at least eight weeks after the presumed time of maternal infection. (See
         <a class="local">
          'Diagnosis'
         </a>
         above and
         <a class="local">
          'Diagnostic amniocentesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Predicting postnatal prognosis
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The predicted outcome of first-trimester primary infection is shown in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef141978" href="/z/d/graphic/141978.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Serial ultrasound examinations at two- to four-week intervals can be useful to detect development of sonographic abnormalities, which can appear 12 or more weeks after a periconceptional or early pregnancy maternal infection, or not at all. An abnormal fetal ultrasound examination suggests a poor postnatal prognosis, but a normal ultrasound examination does not exclude the possibility of a symptomatic neonate or development of long-term neurologic morbidity, especially after first-trimester infection. There are no fetal imaging findings specifically predictive of postnatal hearing loss. (See
         <a class="local">
          'Predicting outcome after confirmation of fetal infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of congenital CMV infection
         </strong>
         – Data on late pregnancy initiation of maternal
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         administration for treatment of infected fetuses are limited and have not demonstrated an improvement in serious CMV-related perinatal outcomes (eg, perinatal death, anomalies on follow-up prenatal or postnatal imaging, postnatal neurological symptoms and hearing loss). (See
         <a class="local">
          'Antiviral medication'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Prevention of congenital CMV infection
         </strong>
         – For patients with periconception or first-trimester primary CMV infection, we suggest high-dose
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         rather than no therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Emerging evidence suggests that maternal antiviral therapy with high-dose oral valacyclovir may substantially reduce the risk of congenital infection, especially if begun prior to 14 weeks gestation and within eight weeks of the maternal infection. However, high-dose valacyclovir (8 grams daily in two to four doses) can have serious maternal side effects (reversible kidney failure in 2 percent of patients) and appears to impact the natural history of maternal adaptive immunity. (See
         <a class="local">
          'Antiviral medication'
         </a>
         above and
         <a class="local">
          'Other agents'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Prevention of maternal CMV infection
         </strong>
         – Approximately 2 percent of seronegative pregnant individuals will contract a primary CMV infection during pregnancy, but this risk can be reduced with use of preventative hygiene interventions (eg, good hand hygiene, minimizing exposure to body fluids from high-risk individuals, and using CMV-negative blood products when transfusing seronegative pregnant individuals). (See
         <a class="local">
          'Strategies for prevention of maternal and/or fetal infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         <strong>
          ACKNOWLEDGMENT
         </strong>
         — The UpToDate editorial staff acknowledges Jeanne S Sheffield, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Ssentongo P, Hehnly C, Birungi P, et al. Congenital Cytomegalovirus Infection Burden and Epidemiologic Risk Factors in Countries With Universal Screening: A Systematic Review and Meta-analysis. JAMA Netw Open 2021; 4:e2120736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 2007; 17:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ornoy A, Diav-Citrin O. Fetal effects of primary and secondary cytomegalovirus infection in pregnancy. Reprod Toxicol 2006; 21:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Staras SA, Dollard SC, Radford KW, et al. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 2006; 43:1143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mussi-Pinhata MM, Yamamoto AY, Moura Brito RM, et al. Birth prevalence and natural history of congenital cytomegalovirus infection in a highly seroimmune population. Clin Infect Dis 2009; 49:522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fowler KB, Ross SA, Shimamura M, et al. Racial and Ethnic Differences in the Prevalence of Congenital Cytomegalovirus Infection. J Pediatr 2018; 200:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fowler KB, Stagno S, Pass RF, et al. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 1992; 326:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pathirana J, Groome M, Dorfman J, et al. Prevalence of Congenital Cytomegalovirus Infection and Associated Risk of In Utero Human Immunodeficiency Virus (HIV) Acquisition in a High-HIV Prevalence Setting, South Africa. Clin Infect Dis 2019; 69:1789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazzarotto T, Guerra B, Gabrielli L, et al. Update on the prevention, diagnosis and management of cytomegalovirus infection during pregnancy. Clin Microbiol Infect 2011; 17:1285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fowler KB, McCollister FP, Dahle AJ, et al. Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection. J Pediatr 1997; 130:624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Istas AS, Demmler GJ, Dobbins JG, Stewart JA. Surveillance for congenital cytomegalovirus disease: a report from the National Congenital Cytomegalovirus Disease Registry. Clin Infect Dis 1995; 20:665.
          </a>
         </li>
         <li class="breakAll">
          Stagno S, Britt W. Cytomegalovirus infections. In: Infectious Diseases of the Fetus and Newborn Infant, 6th ed, Remington JS, Klein JO, Wilson CB, Baker CJ (Eds), Elsevier Saunders, Philadelphia 2006. p.739.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manicklal S, Emery VC, Lazzarotto T, et al. The "silent" global burden of congenital cytomegalovirus. Clin Microbiol Rev 2013; 26:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbosa NG, Yamamoto AY, Duarte G, et al. Cytomegalovirus Shedding in Seropositive Pregnant Women From a High-Seroprevalence Population: The Brazilian Cytomegalovirus Hearing and Maternal Secondary Infection Study. Clin Infect Dis 2018; 67:743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis NL, King CC, Kourtis AP. Cytomegalovirus infection in pregnancy. Birth Defects Res 2017; 109:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zuhair M, Smit GSA, Wallis G, et al. Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis. Rev Med Virol 2019; 29:e2034.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mussi-Pinhata MM, Yamamoto AY. Natural History of Congenital Cytomegalovirus Infection in Highly Seropositive Populations. J Infect Dis 2020; 221:S15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fowler KB, Pass RF. Sexually transmitted diseases in mothers of neonates with congenital cytomegalovirus infection. J Infect Dis 1991; 164:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pass RF, Hutto C, Lyon MD, Cloud G. Increased rate of cytomegalovirus infection among day care center workers. Pediatr Infect Dis J 1990; 9:465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 2003; 289:1008.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gratacap-Cavallier B, Bosson JL, Morand P, et al. Cytomegalovirus seroprevalence in French pregnant women: parity and place of birth as major predictive factors. Eur J Epidemiol 1998; 14:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rudd IP, Marzan MB, Hui L. Cytomegalovirus serological screening at the first antenatal visit: A tertiary-centre audit of general practitioner practices and maternal seroprevalence. Aust N Z J Obstet Gynaecol 2023; 63:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lantos PM, Hoffman K, Permar SR, et al. Neighborhood Disadvantage is Associated with High Cytomegalovirus Seroprevalence in Pregnancy. J Racial Ethn Health Disparities 2018; 5:782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hyde TB, Schmid DS, Cannon MJ. Cytomegalovirus seroconversion rates and risk factors: implications for congenital CMV. Rev Med Virol 2010; 20:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mussi-Pinhata MM, Yamamoto AY, Aragon DC, et al. Seroconversion for Cytomegalovirus Infection During Pregnancy and Fetal Infection in a Highly Seropositive Population: "The BraCHS Study". J Infect Dis 2018; 218:1200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamada M, Komori A, Chiba S, Nakao T. A prospective study of congenital cytomegalovirus infection in Japan. Scand J Infect Dis 1983; 15:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Numazaki K, Fujikawa T, Chiba S. Relationship between seropositivity of husbands and primary cytomegalovirus infection during pregnancy. J Infect Chemother 2000; 6:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hughes BL, Clifton RG, Rouse DJ, et al. A Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus Infection. N Engl J Med 2021; 385:436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leruez-Ville M, Guilleminot T, Stirnemann J, et al. Quantifying the Burden of Congenital Cytomegalovirus Infection With Long-term Sequelae in Subsequent Pregnancies of Women Seronegative at Their First Pregnancy. Clin Infect Dis 2020; 71:1598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nigro G, Anceschi MM, Cosmi EV, Congenital Cytomegalic Disease Collaborating Group. Clinical manifestations and abnormal laboratory findings in pregnant women with primary cytomegalovirus infection. BJOG 2003; 110:572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xie M, Tripathi T, Holmes NE, Hui L. Serological screening for cytomegalovirus during pregnancy: A systematic review of clinical practice guidelines and consensus statements. Prenat Diagn 2023; 43:959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beloosesky R, Feldblum I, Shrim A, et al. Trends in Continuity of Pregnancy in Women with Positive Cytomegalovirus IgM during the First Trimester, 2008-2009. Isr Med Assoc J 2017; 19:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Billette de Villemeur A, Tattevin P, Salmi LR, French Haut Conseil de la santé publique Working Group. Hygiene promotion might be better than serological screening to deal with Cytomegalovirus infection during pregnancy: a methodological appraisal and decision analysis. BMC Infect Dis 2020; 20:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chatzakis C, Shahar-Nissan K, Faure-Bardon V, et al. The effect of valacyclovir on secondary prevention of congenital cytomegalovirus infection, following primary maternal infection acquired periconceptionally or in the first trimester of pregnancy. An individual patient data meta-analysis. Am J Obstet Gynecol 2023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Périllaud-Dubois C, Hachicha-Maalej N, Lepers C, et al. Cost-effectiveness of screening and valacyclovir-based treatment strategies for first-trimester cytomegalovirus primary infection in pregnant women in France. Ultrasound Obstet Gynecol 2023; 62:573.
          </a>
         </li>
         <li class="breakAll">
          Center for Disease Control. Knowledge and Practices of Obstetricians and Gynecologists Regarding Cytomegalovirus Infection During Pregnancy - United States, 2007 https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5703a2.htm (Accessed on October 21, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eggers M, Bäder U, Enders G. Combination of microneutralization and avidity assays: improved diagnosis of recent primary human cytomegalovirus infection in single serum sample of second trimester pregnancy. J Med Virol 2000; 60:324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazzarotto T, Ripalti A, Bergamini G, et al. Development of a new cytomegalovirus (CMV) immunoglobulin M (IgM) immunoblot for detection of CMV-specific IgM. J Clin Microbiol 1998; 36:3337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grangeot-Keros L, Mayaux MJ, Lebon P, et al. Value of cytomegalovirus (CMV) IgG avidity index for the diagnosis of primary CMV infection in pregnant women. J Infect Dis 1997; 175:944.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leruez-Ville M, Sellier Y, Salomon LJ, et al. Prediction of fetal infection in cases with cytomegalovirus immunoglobulin M in the first trimester of pregnancy: a retrospective cohort. Clin Infect Dis 2013; 56:1428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanengisser-Pines B, Hazan Y, Pines G, Appelman Z. High cytomegalovirus IgG avidity is a reliable indicator of past infection in patients with positive IgM detected during the first trimester of pregnancy. J Perinat Med 2009; 37:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rawlinson WD, Boppana SB, Fowler KB, et al. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. Lancet Infect Dis 2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Revello MG, Genini E, Gorini G, et al. Comparative evaluation of eight commercial human cytomegalovirus IgG avidity assays. J Clin Virol 2010; 48:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Enders G, Daiminger A, Bäder U, et al. The value of CMV IgG avidity and immunoblot for timing the onset of primary CMV infection in pregnancy. J Clin Virol 2013; 56:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prince HE, Lapé-Nixon M. Role of cytomegalovirus (CMV) IgG avidity testing in diagnosing primary CMV infection during pregnancy. Clin Vaccine Immunol 2014; 21:1377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chatzakis C, Ville Y, Makrydimas G, et al. Timing of primary maternal cytomegalovirus infection and rates of vertical transmission and fetal consequences. Am J Obstet Gynecol 2020; 223:870.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Picone O, Vauloup-Fellous C, Cordier AG, et al. A series of 238 cytomegalovirus primary infections during pregnancy: description and outcome. Prenat Diagn 2013; 33:751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Enders G, Daiminger A, Bäder U, et al. Intrauterine transmission and clinical outcome of 248 pregnancies with primary cytomegalovirus infection in relation to gestational age. J Clin Virol 2011; 52:244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faure-Bardon V, Magny JF, Parodi M, et al. Sequelae of Congenital Cytomegalovirus Following Maternal Primary Infections Are Limited to Those Acquired in the First Trimester of Pregnancy. Clin Infect Dis 2019; 69:1526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross SA, Novak Z, Pati S, et al. Mixed infection and strain diversity in congenital cytomegalovirus infection. J Infect Dis 2011; 204:1003.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang C, Zhang X, Bialek S, Cannon MJ. Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection. Clin Infect Dis 2011; 52:e11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mwaanza N, Chilukutu L, Tembo J, et al. High rates of congenital cytomegalovirus infection linked with maternal HIV infection among neonatal admissions at a large referral center in sub-Saharan Africa. Clin Infect Dis 2014; 58:728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manicklal S, van Niekerk AM, Kroon SM, et al. Birth prevalence of congenital cytomegalovirus among infants of HIV-infected women on prenatal antiretroviral prophylaxis in South Africa. Clin Infect Dis 2014; 58:1467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellington SR, Clarke KE, Kourtis AP. Cytomegalovirus Infection in Human Immunodeficiency Virus (HIV)-Exposed and HIV-Infected Infants: A Systematic Review. J Infect Dis 2016; 213:891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adachi K, Xu J, Ank B, et al. Congenital Cytomegalovirus and HIV Perinatal Transmission. Pediatr Infect Dis J 2018; 37:1016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frederick T, Homans J, Spencer L, et al. The effect of prenatal highly active antiretroviral therapy on the transmission of congenital and perinatal/early postnatal cytomegalovirus among HIV-infected and HIV-exposed infants. Clin Infect Dis 2012; 55:877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guibert G, Warszawski J, Le Chenadec J, et al. Decreased risk of congenital cytomegalovirus infection in children born to HIV-1-infected mothers in the era of highly active antiretroviral therapy. Clin Infect Dis 2009; 48:1516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tripathi T, Watson J, Holmes NE, et al. The diagnostic accuracy of pooled testing from multiple individuals for the detection of chlamydia trachomatis and neisseria gonorrhoeae: A systematic review. J Paediatr Child Health 2023; 59:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guerra B, Lazzarotto T, Quarta S, et al. Prenatal diagnosis of symptomatic congenital cytomegalovirus infection. Am J Obstet Gynecol 2000; 183:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azam AZ, Vial Y, Fawer CL, et al. Prenatal diagnosis of congenital cytomegalovirus infection. Obstet Gynecol 2001; 97:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liesnard C, Donner C, Brancart F, et al. Prenatal diagnosis of congenital cytomegalovirus infection: prospective study of 237 pregnancies at risk. Obstet Gynecol 2000; 95:881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vauloup-Fellous C, Picone O, Cordier AG, et al. Does hygiene counseling have an impact on the rate of CMV primary infection during pregnancy? Results of a 3-year prospective study in a French hospital. J Clin Virol 2009; 46 Suppl 4:S49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           La Torre R, Nigro G, Mazzocco M, et al. Placental enlargement in women with primary maternal cytomegalovirus infection is associated with fetal and neonatal disease. Clin Infect Dis 2006; 43:994.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simonazzi G, Guerra B, Bonasoni P, et al. Fetal cerebral periventricular halo at midgestation: an ultrasound finding suggestive of fetal cytomegalovirus infection. Am J Obstet Gynecol 2010; 202:599.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malinger G, Lev D, Zahalka N, et al. Fetal cytomegalovirus infection of the brain: the spectrum of sonographic findings. AJNR Am J Neuroradiol 2003; 24:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Picone O, Teissier N, Cordier AG, et al. Detailed in utero ultrasound description of 30 cases of congenital cytomegalovirus infection. Prenat Diagn 2014; 34:518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khalil A, Sotiriadis A, Chaoui R, et al. ISUOG Practice Guidelines: role of ultrasound in congenital infection. Ultrasound Obstet Gynecol 2020; 56:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Enders M, Daiminger A, Exler S, et al. Prenatal diagnosis of congenital cytomegalovirus infection in 115 cases: a 5 years' single center experience. Prenat Diagn 2017; 37:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graham D, Guidi SM, Sanders RC. Sonographic features of in utero periventricular calcification due to cytomegalovirus infection. J Ultrasound Med 1982; 1:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghidini A, Sirtori M, Vergani P, et al. Fetal intracranial calcifications. Am J Obstet Gynecol 1989; 160:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fakhry J, Khoury A. Fetal intracranial calcifications. The importance of periventricular hyperechoic foci without shadowing. J Ultrasound Med 1991; 10:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Estroff JA, Parad RB, Teele RL, Benacerraf BR. Echogenic vessels in the fetal thalami and basal ganglia associated with cytomegalovirus infection. J Ultrasound Med 1992; 11:686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teele RL, Hernanz-Schulman M, Sotrel A. Echogenic vasculature in the basal ganglia of neonates: a sonographic sign of vasculopathy. Radiology 1988; 169:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mittelmann-Handwerker S, Pardes JG, Post RC, et al. Fetal ventriculomegaly and brain atrophy in a woman with intrauterine cytomegalovirus infection. A case report. J Reprod Med 1986; 31:1061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ceballos R, Ch'ien LT, Whitley RJ, Brans YW. Cerebellar hypoplasia in an infant with congenital cytomegalovirus infection. Pediatrics 1976; 57:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shackelford GD, Fulling KH, Glasier CM. Cysts of the subependymal germinal matrix: sonographic demonstration with pathologic correlation. Radiology 1983; 149:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Butt W, Mackay RJ, de Crespigny LC, et al. Intracranial lesions of congenital cytomegalovirus infection detected by ultrasound scanning. Pediatrics 1984; 73:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marques Dias MJ, Harmant-van Rijckevorsel G, Landrieu P, Lyon G. Prenatal cytomegalovirus disease and cerebral microgyria: evidence for perfusion failure, not disturbance of histogenesis, as the major cause of fetal cytomegalovirus encephalopathy. Neuropediatrics 1984; 15:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friede RL, Mikolasek J. Postencephalitic porencephaly, hydranencephaly or polymicrogyria. A review. Acta Neuropathol 1978; 43:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perlman JM, Argyle C. Lethal cytomegalovirus infection in preterm infants: clinical, radiological, and neuropathological findings. Ann Neurol 1992; 31:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drose JA, Dennis MA, Thickman D. Infection in utero: US findings in 19 cases. Radiology 1991; 178:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Twickler DM, Perlman J, Maberry MC. Congenital cytomegalovirus infection presenting as cerebral ventriculomegaly on antenatal sonography. Am J Perinatol 1993; 10:404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore CA, Staples JE, Dobyns WB, et al. Characterizing the Pattern of Anomalies in Congenital Zika Syndrome for Pediatric Clinicians. JAMA Pediatr 2017; 171:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fitzpatrick D, Holmes NE, Hui L. A systematic review of maternal TORCH serology as a screen for suspected fetal infection. Prenat Diagn 2022; 42:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dall'Asta A, Stampalija T, Mecacci F, et al. Incidence, clinical features and perinatal outcome in anomalous fetuses with late-onset growth restriction: cohort study. Ultrasound Obstet Gynecol 2022; 60:632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Society for Maternal-Fetal Medicine (SMFM). Electronic address:
           <span class="__cf_email__" data-cfemail="a2d2d7c0d1e2d1cfc4cf8ccdd0c5">
            [email protected]
           </span>
           , Martins JG, Biggio JR, Abuhamad A. Society for Maternal-Fetal Medicine Consult Series #52: Diagnosis and management of fetal growth restriction: (Replaces Clinical Guideline Number 3, April 2012). Am J Obstet Gynecol 2020; 223:B2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bodéus M, Hubinont C, Bernard P, et al. Prenatal diagnosis of human cytomegalovirus by culture and polymerase chain reaction: 98 pregnancies leading to congenital infection. Prenat Diagn 1999; 19:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dinsmoor MJ, Fette LM, Hughes BL, et al. Amniocentesis to diagnose congenital cytomegalovirus infection following maternal primary infection. Am J Obstet Gynecol MFM 2022; 4:100641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faure-Bardon V, Fourgeaud J, Stirnemann J, et al. Secondary prevention of congenital cytomegalovirus infection with valacyclovir following maternal primary infection in early pregnancy. Ultrasound Obstet Gynecol 2021; 58:576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Enders M, Daiminger A, Exler S, Enders G. Amniocentesis for prenatal diagnosis of cytomegalovirus infection: challenging the 21 weeks' threshold. Prenat Diagn 2017; 37:940.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Revello MG, Furione M, Zavattoni M, et al. Human cytomegalovirus (HCMV) DNAemia in the mother at amniocentesis as a risk factor for iatrogenic HCMV infection of the fetus. J Infect Dis 2008; 197:593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maltezou PG, Kourlaba G, Kourkouni Ε, et al. Maternal type of CMV infection and sequelae in infants with congenital CMV: Systematic review and meta-analysis. J Clin Virol 2020; 129:104518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buca D, Di Mascio D, Rizzo G, et al. Outcome of fetuses with congenital cytomegalovirus infection and normal ultrasound at diagnosis: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2021; 57:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazzarotto T, Varani S, Guerra B, et al. Prenatal indicators of congenital cytomegalovirus infection. J Pediatr 2000; 137:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Revello MG, Zavattoni M, Furione M, et al. Quantification of human cytomegalovirus DNA in amniotic fluid of mothers of congenitally infected fetuses. J Clin Microbiol 1999; 37:3350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leruez-Ville M, Stirnemann J, Sellier Y, et al. Feasibility of predicting the outcome of fetal infection with cytomegalovirus at the time of prenatal diagnosis. Am J Obstet Gynecol 2016; 215:342.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roee B, Adi W, Michael B, et al. Subtle findings on fetal brain imaging in CMV infected pregnancies: What is the clinical significance? A retrospective analysis with outcome correlation. Prenat Diagn 2020; 40:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kyriakopoulou A, Serghiou S, Dimopoulou D, et al. Antenatal imaging and clinical outcome in congenital CMV infection: A field-wide systematic review and meta-analysis. J Infect 2020; 80:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farkas N, Hoffmann C, Ben-Sira L, et al. Does normal fetal brain ultrasound predict normal neurodevelopmental outcome in congenital cytomegalovirus infection? Prenat Diagn 2011; 31:360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fabbri E, Revello MG, Furione M, et al. Prognostic markers of symptomatic congenital human cytomegalovirus infection in fetal blood. BJOG 2011; 118:448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romanelli RM, Magny JF, Jacquemard F. Prognostic markers of symptomatic congenital cytomegalovirus infection. Braz J Infect Dis 2008; 12:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chatzakis C, Sotiriadis A, Dinas K, Ville Y. Neonatal and long-term outcomes of infants with congenital cytomegalovirus infection and negative amniocentesis: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2023; 61:158.
          </a>
         </li>
         <li class="breakAll">
          CMV Fact Sheet for Healthcare Providers. U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/cmv/downloads/identifying-cmv.pdf (Accessed on June 29, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Omarsdottir S, Casper C, Zweygberg Wirgart B, et al. Transmission of cytomegalovirus to extremely preterm infants through breast milk. Acta Paediatr 2007; 96:492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Capretti MG, Lanari M, Lazzarotto T, et al. Very low birth weight infants born to cytomegalovirus-seropositive mothers fed with their mother's milk: a prospective study. J Pediatr 2009; 154:842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maschmann J, Hamprecht K, Dietz K, et al. Cytomegalovirus infection of extremely low-birth weight infants via breast milk. Clin Infect Dis 2001; 33:1998.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pereira L, Petitt M, Fong A, et al. Intrauterine growth restriction caused by underlying congenital cytomegalovirus infection. J Infect Dis 2014; 209:1573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iwasenko JM, Howard J, Arbuckle S, et al. Human cytomegalovirus infection is detected frequently in stillbirths and is associated with fetal thrombotic vasculopathy. J Infect Dis 2011; 203:1526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adler SP, Finney JW, Manganello AM, Best AM. Prevention of child-to-mother transmission of cytomegalovirus by changing behaviors: a randomized controlled trial. Pediatr Infect Dis J 1996; 15:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adler SP, Finney JW, Manganello AM, Best AM. Prevention of child-to-mother transmission of cytomegalovirus among pregnant women. J Pediatr 2004; 145:485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Revello MG, Tibaldi C, Masuelli G, et al. Prevention of Primary Cytomegalovirus Infection in Pregnancy. EBioMedicine 2015; 2:1205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barber V, Calvert A, Vandrevala T, et al. Prevention of Acquisition of Cytomegalovirus Infection in Pregnancy Through Hygiene-based Behavioral Interventions: A Systematic Review and Gap Analysis. Pediatr Infect Dis J 2020; 39:949.
          </a>
         </li>
         <li class="breakAll">
          CMV Fact Sheet for Pregnant Women and Parents. Cytomegalovirus (CMV) and Congenital CMV Infection. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/cmv/fact-sheets/parents-pregnant-women.html (Accessed on June 29, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Revello MG, Zavattoni M, Furione M, et al. Preconceptional primary human cytomegalovirus infection and risk of congenital infection. J Infect Dis 2006; 193:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brosh-Nissimov T, Benshalom-Tirosh N, Bucris E, et al. Recurrent congenital cytomegalovirus infection in a sequential pregnancy with severe sequelae, and a possible association with prophylactic valacyclovir treatment: a case report. Int J Infect Dis 2022; 125:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Antonio F, Marinceu D, Prasad S, Khalil A. Effectiveness and safety of prenatal valacyclovir for congenital cytomegalovirus infection: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2023; 61:436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shahar-Nissan K, Pardo J, Peled O, et al. Valaciclovir to prevent vertical transmission of cytomegalovirus after maternal primary infection during pregnancy: a randomised, double-blind, placebo-controlled trial. Lancet 2020; 396:779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amir J, Chodick G, Pardo J. Revised Protocol for Secondary Prevention of Congenital Cytomegalovirus Infection With Valaciclovir Following Infection in Early Pregnancy. Clin Infect Dis 2023; 77:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huntjens DW, Dijkstra JA, Verwiel LN, et al. Optimizing Antiviral Dosing for HSV and CMV Treatment in Immunocompromised Patients. Pharmaceutics 2023; 15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zammarchi L, Tomasoni LR, Liuzzi G, et al. Treatment with valacyclovir during pregnancy for prevention of congenital cytomegalovirus infection: a real-life multicenter Italian observational study. Am J Obstet Gynecol MFM 2023; 5:101101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leruez-Ville M, Ghout I, Bussières L, et al. In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study. Am J Obstet Gynecol 2016; 215:462.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Revello MG, Lazzarotto T, Guerra B, et al. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med 2014; 370:1316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hughes BL, Clifton RG, Rouse DJ, et al. Randomized Trial of Hyperimmune Globulin for Congenital CMV Infection - 2-Year Outcomes. N Engl J Med 2023; 389:1822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kagan KO, Enders M, Schampera MS, et al. Prevention of maternal-fetal transmission of cytomegalovirus after primary maternal infection in the first trimester by biweekly hyperimmunoglobulin administration. Ultrasound Obstet Gynecol 2019; 53:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kagan KO, Enders M, Hoopmann M, et al. Outcome of pregnancies with recent primary cytomegalovirus infection in first trimester treated with hyperimmunoglobulin: observational study. Ultrasound Obstet Gynecol 2021; 57:560.
          </a>
         </li>
         <li class="breakAll">
          Vaccines for the 21st Century: A Tool for Decisionmaking, Institute of Medicine (US) Committee to Study Priorities for Vaccine Development. (Ed), National Academies Press (US), Washington (DC) 2000.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pass RF, Zhang C, Evans A, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 2009; 360:1191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernstein DI, Munoz FM, Callahan ST, et al. Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial. Vaccine 2016; 34:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Das R, Blázquez-Gamero D, Bernstein DI, et al. Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Infect Dis 2023; 23:1383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Semmes EC, Miller IG, Wimberly CE, et al. Maternal Fc-mediated non-neutralizing antibody responses correlate with protection against congenital human cytomegalovirus infection. J Clin Invest 2022; 132.
          </a>
         </li>
         <li class="breakAll">
          A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age. ClinicalTrials.gov. Available at: https://classic.clinicaltrials.gov/ct2/show/NCT05085366 (Accessed on June 29, 2023).
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4810 Version 88.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34424308" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Congenital Cytomegalovirus Infection Burden and Epidemiologic Risk Factors in Countries With Universal Screening: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17579921" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16580941" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Fetal effects of primary and secondary cytomegalovirus infection in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17029132" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Seroprevalence of cytomegalovirus infection in the United States, 1988-1994.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19583520" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Birth prevalence and natural history of congenital cytomegalovirus infection in a highly seroimmune population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29784513" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Racial and Ethnic Differences in the Prevalence of Congenital Cytomegalovirus Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1310525" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The outcome of congenital cytomegalovirus infection in relation to maternal antibody status.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30615106" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Prevalence of Congenital Cytomegalovirus Infection and Associated Risk of In Utero Human Immunodeficiency Virus (HIV) Acquisition in a High-HIV Prevalence Setting, South Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21631642" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Update on the prevention, diagnosis and management of cytomegalovirus infection during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9108862" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7756493" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Surveillance for congenital cytomegalovirus disease: a report from the National Congenital Cytomegalovirus Disease Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7756493" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Surveillance for congenital cytomegalovirus disease: a report from the National Congenital Cytomegalovirus Disease Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23297260" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The "silent" global burden of congenital cytomegalovirus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29490030" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Cytomegalovirus Shedding in Seropositive Pregnant Women From a High-Seroprevalence Population: The Brazilian Cytomegalovirus Hearing and Maternal Secondary Infection Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28398680" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Cytomegalovirus infection in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30706584" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32134482" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Natural History of Congenital Cytomegalovirus Infection in Highly Seropositive Populations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1649872" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Sexually transmitted diseases in mothers of neonates with congenital cytomegalovirus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1973533" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Increased rate of cytomegalovirus infection among day care center workers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12597753" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Maternal immunity and prevention of congenital cytomegalovirus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9556173" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Cytomegalovirus seroprevalence in French pregnant women: parity and place of birth as major predictive factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36722334" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Cytomegalovirus serological screening at the first antenatal visit: A tertiary-centre audit of general practitioner practices and maternal seroprevalence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28840519" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Neighborhood Disadvantage is Associated with High Cytomegalovirus Seroprevalence in Pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20645278" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Cytomegalovirus seroconversion rates and risk factors: implications for congenital CMV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29868783" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Seroconversion for Cytomegalovirus Infection During Pregnancy and Fetal Infection in a Highly Seropositive Population: "The BraCHS Study".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6316478" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : A prospective study of congenital cytomegalovirus infection in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11810545" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Relationship between seropositivity of husbands and primary cytomegalovirus infection during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34320288" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : A Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31665306" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Quantifying the Burden of Congenital Cytomegalovirus Infection With Long-term Sequelae in Subsequent Pregnancies of Women Seronegative at Their First Pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12798474" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Clinical manifestations and abnormal laboratory findings in pregnant women with primary cytomegalovirus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37309996" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Serological screening for cytomegalovirus during pregnancy: A systematic review of clinical practice guidelines and consensus statements.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28825766" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Trends in Continuity of Pregnancy in Women with Positive Cytomegalovirus IgM during the First Trimester, 2008-2009.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32546244" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Hygiene promotion might be better than serological screening to deal with Cytomegalovirus infection during pregnancy: a methodological appraisal and decision analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37473793" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The effect of valacyclovir on secondary prevention of congenital cytomegalovirus infection, following primary maternal infection acquired periconceptionally or in the first trimester of pregnancy. An individual patient data meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37099516" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Cost-effectiveness of screening and valacyclovir-based treatment strategies for first-trimester cytomegalovirus primary infection in pregnant women in France.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37099516" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Cost-effectiveness of screening and valacyclovir-based treatment strategies for first-trimester cytomegalovirus primary infection in pregnant women in France.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10630965" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Combination of microneutralization and avidity assays: improved diagnosis of recent primary human cytomegalovirus infection in single serum sample of second trimester pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9774589" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Development of a new cytomegalovirus (CMV) immunoglobulin M (IgM) immunoblot for detection of CMV-specific IgM.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9086155" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Value of cytomegalovirus (CMV) IgG avidity index for the diagnosis of primary CMV infection in pregnant women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23392397" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Prediction of fetal infection in cases with cytomegalovirus immunoglobulin M in the first trimester of pregnancy: a retrospective cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18673093" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : High cytomegalovirus IgG avidity is a reliable indicator of past infection in patients with positive IgM detected during the first trimester of pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28291720" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20561816" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Comparative evaluation of eight commercial human cytomegalovirus IgG avidity assays.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23153820" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : The value of CMV IgG avidity and immunoblot for timing the onset of primary CMV infection in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25165026" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Role of cytomegalovirus (CMV) IgG avidity testing in diagnosing primary CMV infection during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32460972" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Timing of primary maternal cytomegalovirus infection and rates of vertical transmission and fetal consequences.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23553686" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : A series of 238 cytomegalovirus primary infections during pregnancy: description and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21820954" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Intrauterine transmission and clinical outcome of 248 pregnancies with primary cytomegalovirus infection in relation to gestational age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30596974" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Sequelae of Congenital Cytomegalovirus Following Maternal Primary Infections Are Limited to Those Acquired in the First Trimester of Pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21881114" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Mixed infection and strain diversity in congenital cytomegalovirus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21288834" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24265360" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : High rates of congenital cytomegalovirus infection linked with maternal HIV infection among neonatal admissions at a large referral center in sub-Saharan Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24567248" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Birth prevalence of congenital cytomegalovirus among infants of HIV-infected women on prenatal antiretroviral prophylaxis in South Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26597258" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Cytomegalovirus Infection in Human Immunodeficiency Virus (HIV)-Exposed and HIV-Infected Infants: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30216294" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Congenital Cytomegalovirus and HIV Perinatal Transmission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22675157" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : The effect of prenatal highly active antiretroviral therapy on the transmission of congenital and perinatal/early postnatal cytomegalovirus among HIV-infected and HIV-exposed infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19388872" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Decreased risk of congenital cytomegalovirus infection in children born to HIV-1-infected mothers in the era of highly active antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : The diagnostic accuracy of pooled testing from multiple individuals for the detection of chlamydia trachomatis and neisseria gonorrhoeae: A systematic review
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10942490" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Prenatal diagnosis of symptomatic congenital cytomegalovirus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11239654" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Prenatal diagnosis of congenital cytomegalovirus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10831985" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Prenatal diagnosis of congenital cytomegalovirus infection: prospective study of 237 pregnancies at risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19811947" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Does hygiene counseling have an impact on the rate of CMV primary infection during pregnancy? Results of a 3-year prospective study in a French hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16983610" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Placental enlargement in women with primary maternal cytomegalovirus infection is associated with fetal and neonatal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20227051" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Fetal cerebral periventricular halo at midgestation: an ultrasound finding suggestive of fetal cytomegalovirus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12533323" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Fetal cytomegalovirus infection of the brain: the spectrum of sonographic findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24532345" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Detailed in utero ultrasound description of 30 cases of congenital cytomegalovirus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32400006" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : ISUOG Practice Guidelines: role of ultrasound in congenital infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28207161" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Prenatal diagnosis of congenital cytomegalovirus infection in 115 cases: a 5 years' single center experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6152949" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Sonographic features of in utero periventricular calcification due to cytomegalovirus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2536222" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Fetal intracranial calcifications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1847726" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Fetal intracranial calcifications. The importance of periventricular hyperechoic foci without shadowing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1337361" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Echogenic vessels in the fetal thalami and basal ganglia associated with cytomegalovirus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2845473" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Echogenic vasculature in the basal ganglia of neonates: a sonographic sign of vasculopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3027325" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Fetal ventriculomegaly and brain atrophy in a woman with intrauterine cytomegalovirus infection. A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/174055" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Cerebellar hypoplasia in an infant with congenital cytomegalovirus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6310678" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Cysts of the subependymal germinal matrix: sonographic demonstration with pathologic correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6326039" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Intracranial lesions of congenital cytomegalovirus infection detected by ultrasound scanning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6324014" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Prenatal cytomegalovirus disease and cerebral microgyria: evidence for perfusion failure, not disturbance of histogenesis, as the major cause of fetal cytomegalovirus encephalopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/567000" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Postencephalitic porencephaly, hydranencephaly or polymicrogyria. A review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1311911" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Lethal cytomegalovirus infection in preterm infants: clinical, radiological, and neuropathological findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1846239" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Infection in utero: US findings in 19 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8240605" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Congenital cytomegalovirus infection presenting as cerebral ventriculomegaly on antenatal sonography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27812690" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Characterizing the Pattern of Anomalies in Congenital Zika Syndrome for Pediatric Clinicians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34893980" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : A systematic review of maternal TORCH serology as a screen for suspected fetal infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35638182" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Incidence, clinical features and perinatal outcome in anomalous fetuses with late-onset growth restriction: cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32407785" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Society for Maternal-Fetal Medicine Consult Series #52: Diagnosis and management of fetal growth restriction: (Replaces Clinical Guideline Number 3, April 2012).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10327134" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Prenatal diagnosis of human cytomegalovirus by culture and polymerase chain reaction: 98 pregnancies leading to congenital infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35526782" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Amniocentesis to diagnose congenital cytomegalovirus infection following maternal primary infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33998084" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Secondary prevention of congenital cytomegalovirus infection with valacyclovir following maternal primary infection in early pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28677115" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Amniocentesis for prenatal diagnosis of cytomegalovirus infection: challenging the 21 weeks' threshold.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18275277" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Human cytomegalovirus (HCMV) DNAemia in the mother at amniocentesis as a risk factor for iatrogenic HCMV infection of the fetus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32622333" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Maternal type of CMV infection and sequelae in infants with congenital CMV: Systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33030767" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Outcome of fetuses with congenital cytomegalovirus infection and normal ultrasound at diagnosis: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10891828" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Prenatal indicators of congenital cytomegalovirus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10488204" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Quantification of human cytomegalovirus DNA in amniotic fluid of mothers of congenitally infected fetuses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27063062" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Feasibility of predicting the outcome of fetal infection with cytomegalovirus at the time of prenatal diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31875430" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Subtle findings on fetal brain imaging in CMV infected pregnancies: What is the clinical significance? A retrospective analysis with outcome correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32097687" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Antenatal imaging and clinical outcome in congenital CMV infection: A field-wide systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21413035" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Does normal fetal brain ultrasound predict normal neurodevelopmental outcome in congenital cytomegalovirus infection?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21199291" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Prognostic markers of symptomatic congenital human cytomegalovirus infection in fetal blood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18553012" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Prognostic markers of symptomatic congenital cytomegalovirus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36412976" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Neonatal and long-term outcomes of infants with congenital cytomegalovirus infection and negative amniocentesis: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36412976" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Neonatal and long-term outcomes of infants with congenital cytomegalovirus infection and negative amniocentesis: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17391465" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Transmission of cytomegalovirus to extremely preterm infants through breast milk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19230896" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Very low birth weight infants born to cytomegalovirus-seropositive mothers fed with their mother's milk: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11712092" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Cytomegalovirus infection of extremely low-birth weight infants via breast milk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24403553" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Intrauterine growth restriction caused by underlying congenital cytomegalovirus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21592980" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Human cytomegalovirus infection is detected frequently in stillbirths and is associated with fetal thrombotic vasculopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8852913" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Prevention of child-to-mother transmission of cytomegalovirus by changing behaviors: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15480372" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Prevention of child-to-mother transmission of cytomegalovirus among pregnant women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26501119" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Prevention of Primary Cytomegalovirus Infection in Pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32502127" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Prevention of Acquisition of Cytomegalovirus Infection in Pregnancy Through Hygiene-based Behavioral Interventions: A Systematic Review and Gap Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32502127" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Prevention of Acquisition of Cytomegalovirus Infection in Pregnancy Through Hygiene-based Behavioral Interventions: A Systematic Review and Gap Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16479511" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Preconceptional primary human cytomegalovirus infection and risk of congenital infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36229004" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Recurrent congenital cytomegalovirus infection in a sequential pregnancy with severe sequelae, and a possible association with prophylactic valacyclovir treatment: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36484439" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Effectiveness and safety of prenatal valacyclovir for congenital cytomegalovirus infection: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32919517" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Valaciclovir to prevent vertical transmission of cytomegalovirus after maternal primary infection during pregnancy: a randomised, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37157938" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Revised Protocol for Secondary Prevention of Congenital Cytomegalovirus Infection With Valaciclovir Following Infection in Early Pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36678792" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Optimizing Antiviral Dosing for HSV and CMV Treatment in Immunocompromised Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37516151" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Treatment with valacyclovir during pregnancy for prevention of congenital cytomegalovirus infection: a real-life multicenter Italian observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27083761" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24693891" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37937785" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Randomized Trial of Hyperimmune Globulin for Congenital CMV Infection - 2-Year Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29947159" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Prevention of maternal-fetal transmission of cytomegalovirus after primary maternal infection in the first trimester by biweekly hyperimmunoglobulin administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33491819" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Outcome of pregnancies with recent primary cytomegalovirus infection in first trimester treated with hyperimmunoglobulin: observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33491819" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Outcome of pregnancies with recent primary cytomegalovirus infection in first trimester treated with hyperimmunoglobulin: observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19297572" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Vaccine prevention of maternal cytomegalovirus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26657184" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37660711" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35763348" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Maternal Fc-mediated non-neutralizing antibody responses correlate with protection against congenital human cytomegalovirus infection.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
